Gastroesophageal Reflux Disease
| Autor: | Kim A. Noble |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
business.industry General surgery Pharmacological management Adult population Reflux Disease Middle Aged medicine.disease digestive system diseases Pharmacological treatment Medical–Surgical Nursing Gastroesophageal Reflux medicine GERD Selling drugs Humans Female Intensive care medicine business Pediatric population |
| Zdroj: | Journal of PeriAnesthesia Nursing. 28:102-106 |
| ISSN: | 1089-9472 |
| DOI: | 10.1016/j.jopan.2013.01.004 |
| Popis: | THERE ARE AN estimated 75 million individuals with gastroesophageal reflux disease (GERD) in the United States. This disease is not limited to the adult population, with approximately 22% of the pediatric population also affected. Individuals undergoingelective surgery frequently report a history of GERD with 14% to 20% of all adults reporting symptoms associated with reflux disease. Proton pump inhibitors (PPIs) are the first-line pharmacologic treatment for GERD and are among the five top selling drugs, with an estimated 10 billion dollars spent on PPIs in the United States annually. Client preparation for elective or emergent surgery includes assessment and the proactive planning for safe discharge. The perianesthesia care provider needs to have a comprehensive understanding of this common disorder and its surgical and pharmacologic management. The pathophysiology of GERD and evidencebased treatment modalities will be presented in a fictitious perianesthesia patient case study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect